Difference between revisions of "Irinotecan (Camptosar)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=533 Irinotecan (Camptosar) package insert]</ref><ref>[http://hemonc.o...") |
|||
| Line 1: | Line 1: | ||
| + | Also known as CPT-11. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=533 Irinotecan (Camptosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/irinotecan.pdf Irinotecan (Camptosar) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible |
| − | <br>Route: | + | single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase |
| − | <br>Extravasation: | + | I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=533 Irinotecan (Camptosar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/irinotecan.pdf Irinotecan (Camptosar) package insert (locally hosted backup)]</ref> |
| + | <br>Route: IV | ||
| + | <br>Extravasation: [[irritant]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
Revision as of 17:02, 22 February 2012
Also known as CPT-11.
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible
single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase
I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]